ADC Therapeutics SA Key Management Personnel Compensation Other Longterm Benefits
ADC Therapeutics SA (ADCT) reported Key Management Personnel Compensation Other Longterm Benefits of $32.00 thousand for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits · last filed 2023-11-07
- ADC Therapeutics SA key management personnel compensation other longterm benefits for the quarter ending 2023-09-30 was $32.00K, a 357.14% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation other longterm benefits for the quarter ending 2023-06-30 was $33.00K, a 312.50% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation other longterm benefits for the quarter ending 2023-03-31 was $38.00K, a 280.00% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation other longterm benefits for the quarter ending 2022-12-31 was $216.00K, a 100.00% increase year-over-year.
| Period end | Key Management Personnel Compensation Other Longterm Benefits 3 month | Key Management Personnel Compensation Other Longterm Benefits 6 month | Key Management Personnel Compensation Other Longterm Benefits 9 month | Key Management Personnel Compensation Other Longterm Benefits 12 month |
|---|---|---|---|---|
| 2023-09-30 | $32.00K 6-K · filed 2023-11-07 | $65.00K derived: sum of 2 quarters · filed 2023-11-07 | $103.00K 6-K · filed 2023-11-07 | $319.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $33.00K 6-K · filed 2023-08-08 | $71.00K 6-K · filed 2023-08-08 | $287.00K derived: sum of 3 quarters · filed 2023-08-08 | $294.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $38.00K 6-K · filed 2023-05-09 | $254.00K derived: sum of 2 quarters · filed 2023-05-09 | $261.00K derived: sum of 3 quarters · filed 2023-11-07 | $269.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $216.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $223.00K derived: sum of 2 quarters · filed 2023-11-07 | $231.00K derived: sum of 3 quarters · filed 2023-11-07 | $241.00K 20-F · filed 2023-03-15 |
| 2022-09-30 | $7.00K 6-K · filed 2023-11-07 | $15.00K derived: sum of 2 quarters · filed 2023-11-07 | $25.00K 6-K · filed 2023-11-07 | $133.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $8.00K 6-K · filed 2023-08-08 | $18.00K 6-K · filed 2023-08-08 | $126.00K derived: sum of 3 quarters · filed 2023-08-08 | $138.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $10.00K 6-K · filed 2023-05-09 | $118.00K derived: sum of 2 quarters · filed 2023-05-09 | $130.00K derived: sum of 3 quarters · filed 2023-05-09 | $139.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $108.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $120.00K derived: sum of 2 quarters · filed 2023-03-15 | $129.00K derived: sum of 3 quarters · filed 2023-03-15 | $142.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | $12.00K 6-K · filed 2022-11-08 | $21.00K derived: sum of 2 quarters · filed 2022-11-08 | $34.00K 6-K · filed 2022-11-08 | $138.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $9.00K 6-K · filed 2022-08-09 | $22.00K 6-K · filed 2022-08-09 | $126.00K derived: sum of 3 quarters · filed 2023-03-15 | $135.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $13.00K 6-K · filed 2022-05-09 | $117.00K derived: sum of 2 quarters · filed 2023-03-15 | $126.00K derived: sum of 3 quarters · filed 2023-03-15 | $148.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $104.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $113.00K derived: sum of 2 quarters · filed 2023-03-15 | $135.00K derived: sum of 3 quarters · filed 2023-03-15 | $196.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | $9.00K 6-K · filed 2021-11-02 | $31.00K derived: sum of 2 quarters · filed 2021-11-02 | $92.00K 6-K · filed 2021-11-02 | |
| 2020-06-30 | $22.00K 6-K · filed 2021-08-03 | $83.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $62.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $73.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $183.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |